September 9 – 12, 2019

Westin Boston Waterfront

Boston, MA

In this shifting healthcare paradigm and with emerging technology, such as liquid biopsies and multiplexing, generating novel biomarker signatures that are demonstrating their predictive power for patient selection and treatment decisions, now is the time to harness a fully fledged biomarker-diagnostic platform to efficiently bring your targeted drug candidates to market.

Within oncology, competition is fierce for specific patient populations and in other complex disease indications (such as cardiovascular, CNS, autoimmune and rare diseases) momentum is gaining for the use of patient stratifying diagnostics to close the gap on unmet patient need.

Built for diagnostic, precision medicine and commercial leads, this half of the meeting will provide insight into the maturation of disruptive technology, simultaneously tackling obstacles in reimbursement and commercialization to ensure the maximization of a diagnostic’s global footprint and implementation in healthcare.

Be at the pinnacle of crucial and candid conversation to discover why, how and when to adopt a CDx strategy early in your drug development programs and ensure you have the right collaboration to ultimately deliver a CDx strategy that brings true value to the market uptake of your drug.

Key topics addressed in 2018:

  • Building a commercial strategy to achieve a global footprint for precision medicine and its associated test
  • Overcoming hurdles in reimbursement for diagnostic enabled therapeutics to improve adoption and uptake in healthcare
  • Accelerating the demonstration of clinical utility and regulatory success for diagnostic-enabled precision medicines
  • Improving drug-IVD co-development to streamline the clinical development, approval and launch of a drug-Dx product